Day: June 16, 2025

        Company Announcement No 27/2025Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk16 June 2025  Dear Sirs Sydbank A/S share buyback programme: transactions in week 24On 26 February 2025 Sydbank A/S announced a share buyback programme of DKK 1,350m. The share buyback programme commenced on 3 March 2025 and will be completed by 31 January 2026. The purpose of the share buyback programme is to reduce the share capital of Sydbank A/S and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under...

 Company announcement no. 29 2025 Danske Bank Bernstorffsgade 40 DK-1577 København V Tel. + 45 33 44 00 00 16 June 2025 Page 1 of 1 Danske Bank share buy-back programme: transactions in week 24 On 7 February 2025, Danske Bank A/S announced a share buy-back programme for a total of DKK 5 billion, with a maximum of 45,000,000 shares, in the period from 10 February 2025 to 30 January 2026, at the latest, as described in company announcement no. 6 2025. The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions on Nasdaq Copenhagen...

New listings reflect growing demand for regulated crypto investment products in the Nordic region Zurich, 16 June 2025 – 21Shares AG, one of the world’s largest issuers of cryptocurrency exchange-traded products (ETPs), today announced the crosslisting of five additional products on Nasdaq Stockholm, further solidifying its presence in the Nordic region and reinforcing its commitment to providing investors with regulated, transparent, and simple access to digital assets. The newly listed products include:21Shares Uniswap ETP (Ticker: AUNI) 21Shares Avalanche ETP (Ticker: AVAX) 21Shares Bitcoin Gold ETP (Ticker: BOLD) 21Shares Solana Core Staking ETP (Ticker: CSOL) 21Shares Ethereum Core ETP (Ticker: ETHC)These products join an existing suite of 21Shares products already available on Nasdaq Stockholm: the 21Shares Bitcoin...

New 50,000-Square-Foot Facility, Located on 20 acres, is Expected to Expand to 100,000 Square Feet and House up to Five GEK Engine Production Lines PARIS, June 16, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a Technology Company in the Defense, National Security and Global Markets, today announced plans to open a new advanced manufacturing facility in Bristow, Oklahoma to produce its GEK (GE Aerospace-Kratos) family of turbojet engines, with an initial focus on the GEK800. The announcement was made during the Oklahoma Breakfast in Paris ahead of the 2025 Paris Air Show, with Kratos CEO Eric DeMarco, Kratos Turbine Technologies (KTT) President Stacey Rock, and Oklahoma Governor Kevin Stitt in attendance.Kratos’ Manufacturing Facility in Bristow, OK A photo accompanying this announcement...

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeDanish Financial Supervisory AuthorityOther stakeholders Date        16 June 2025 Share buyback programme – week 24 The share buyback programme runs in the period 2 June 2025 up to and including 30 January 2026, see company announcement of 2 June 2025. During the period the bank will thus buy back its own shares for a total of up to DKK 1,000 million under the programme, but to a maximum of 1,600,000 shares. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme:Date Number of shares Average purchase price (DKK) Total purchased under the programme...

Disclosure of trading in own shares occurred from June 9 to June 13, 2025 Saint-Cloud, June 16, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from June 9 to June 13, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders’ Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation:Issuer name Issuer code(LEI) Transaction date ISIN Code Daily total Volume (in number of shares) Daily weighted average price of shares acquired (in euros) Platform (MIC Code)ELIS SA 969500UX71LCE8MAY492 06/09/2025 FR0012435121 14,578 23.4539 XPARELIS SA 969500UX71LCE8MAY492 06/09/2025 FR0012435121 7,525 23.4131 DXEELIS SA 969500UX71LCE8MAY492 06/10/2025 FR0012435121 13,651 23.6766 XPARELIS...

Company announcement no. 34 / 2025Schindellegi, Switzerland – 16 June 2025 Trifork Group: Weekly report on share buyback On 28 February 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. For details, please see company announcement no. 7 of 28 February 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share capital. Under the program, the following transactions have been...

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 982,403 537.23 527,780,00710 June 2025 2,000 627.23 1,254,45011 June 2025 14,169 628.91 8,910,96512...

WISeKey Appoints Rolf Gobet to its Strategic Advisory Committee Geneva – June 16, 2025 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announced the appointment of Rolf Gobet to its Strategic Advisory Committee.Mr. Gobet brings over three decades of experience in managing complex public-private projects, as he has held several leadership roles across Europe. As part of HP’s EMEA e-government group, which focuses on providing technological solutions and services to public sector organizations in the Europe, Middle East, and Africa region, Mr. Gobet led the implementation of the world’s first internet voting solution, an achievement made possible through a close collaboration with WISeKey. This initiative set a global benchmark for digital trust...

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression Parkinson’s disease affects over 10 million people globally and significant unmet need remainsBasel, 16 June 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies. “We are encouraged by the efficacy signals observed across...